Treatment of cryptosporidiosis: Do we know what we think we know?

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose of review: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. Recent findings: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. Summary: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.

Original languageEnglish (US)
Pages (from-to)494-499
Number of pages6
JournalCurrent Opinion in Infectious Diseases
Volume23
Issue number5
DOIs
StatePublished - Oct 2010

Fingerprint

Cryptosporidiosis
nitazoxanide
Antiparasitic Agents
Acquired Immunodeficiency Syndrome
Epidemiology
Therapeutics
Paromomycin
HIV
HIV Protease Inhibitors
Research
Pharmaceutical Preparations
Parasites

Keywords

  • Antiretrovirals
  • cryptosporidiosis
  • nitazoxanide
  • paromomycin
  • treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Treatment of cryptosporidiosis : Do we know what we think we know? / Cabada, Miguel; White, A. Clinton.

In: Current Opinion in Infectious Diseases, Vol. 23, No. 5, 10.2010, p. 494-499.

Research output: Contribution to journalArticle

@article{6b81cb1f5c054754888d0450a0657a39,
title = "Treatment of cryptosporidiosis: Do we know what we think we know?",
abstract = "Purpose of review: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. Recent findings: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. Summary: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.",
keywords = "Antiretrovirals, cryptosporidiosis, nitazoxanide, paromomycin, treatment",
author = "Miguel Cabada and White, {A. Clinton}",
year = "2010",
month = "10",
doi = "10.1097/QCO.0b013e32833de052",
language = "English (US)",
volume = "23",
pages = "494--499",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment of cryptosporidiosis

T2 - Do we know what we think we know?

AU - Cabada, Miguel

AU - White, A. Clinton

PY - 2010/10

Y1 - 2010/10

N2 - Purpose of review: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. Recent findings: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. Summary: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.

AB - Purpose of review: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. Recent findings: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. Summary: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.

KW - Antiretrovirals

KW - cryptosporidiosis

KW - nitazoxanide

KW - paromomycin

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=77956231962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956231962&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e32833de052

DO - 10.1097/QCO.0b013e32833de052

M3 - Article

C2 - 20689422

AN - SCOPUS:77956231962

VL - 23

SP - 494

EP - 499

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 5

ER -